News | May 11, 2022
Bayer posts higher sales, profit in first quarter
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Bayer will be setting up 27 telemedicine centres in 12 districts across 8 states with implementing partners Telerad RxDx and Piramal Swasthya
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
Darolutamide is developed jointly by Bayer and Orion Corporation
Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)